The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells - PubMed (original) (raw)
. 2000 Feb 17;19(7):906-15.
doi: 10.1038/sj.onc.1203396.
Affiliations
- PMID: 10702799
- DOI: 10.1038/sj.onc.1203396
The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
D H Wai et al. Oncogene. 2000.
Abstract
The congenital fibrosarcoma t(12;15)(p13;q25) rearrangement splices the ETV6 (TEL) gene on chromosome 12p13 in frame with the NTRK3 (TRKC) neurotrophin-3 receptor gene on chromosome 15q25. Resultant ETV6-NTRK3 fusion transcripts encode the helix - loop - helix (HLH) dimerization domain of ETV6 fused to the protein tyrosine kinase (PTK) domain of NTRK3. We show here that ETV6-NTRK3 homodimerizes and is capable of forming heterodimers with wild-type ETV6. Moreover, ETV6-NTRK3 has PTK activity and is autophosphorylated on tyrosine residues. To determine if the fusion protein has transforming activity, NIH3T3 cells were infected with recombinant retroviral vectors carrying the full-length ETV6-NTRK3 cDNA. These cells exhibited a transformed phenotype, grew macroscopic colonies in soft agar, and formed tumors in severe combined immunodeficient (SCID) mice. We hypothesize that chimeric proteins mediate transformation by dysregulating NTRK3 signal transduction pathways via ligand-independent dimerization and PTK activation. To test this hypothesis, we expressed a series of ETV6-NTRK3 mutants in NIH3T3 cells and assessed their transformation activities. Deletion of the ETV6 HLH domain abolished dimer formation with either ETV6 or ETV6-NTRK3, and cells expressing this mutant protein were morphologically non-transformed and failed to grow in soft agar. An ATP-binding mutant failed to autophosphorylate and completely lacked transformation activity. Mutants of the three NTRK3 PTK activation-loop tyrosines had variable PTK activity but had limited to absent transformation activity. Of a series of signaling molecules well known to bind to wild-type NTRK3, only phospholipase-Cgamma (PLCgamma) associated with ETV6-NTRK3. However, a PTK active mutant unable to bind PLCgamma did not show defects in transformation activity. Our studies confirm that ETV6-NTRK3 is a transforming protein that requires both an intact dimerization domain and a functional PTK domain for transformation activity. Oncogene (2000) 19, 906 - 915.
Similar articles
- Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.
Tognon CE, Mackereth CD, Somasiri AM, McIntosh LP, Sorensen PH. Tognon CE, et al. Mol Cell Biol. 2004 Jun;24(11):4636-50. doi: 10.1128/MCB.24.11.4636-4650.2004. Mol Cell Biol. 2004. PMID: 15143160 Free PMC article. - A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. Knezevich SR, et al. Nat Genet. 1998 Feb;18(2):184-7. doi: 10.1038/ng0298-184. Nat Genet. 1998. PMID: 9462753 - The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
Tognon C, Garnett M, Kenward E, Kay R, Morrison K, Sorensen PH. Tognon C, et al. Cancer Res. 2001 Dec 15;61(24):8909-16. Cancer Res. 2001. PMID: 11751416 - ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages.
Lannon CL, Sorensen PH. Lannon CL, et al. Semin Cancer Biol. 2005 Jun;15(3):215-23. doi: 10.1016/j.semcancer.2005.01.003. Semin Cancer Biol. 2005. PMID: 15826836 Review. - Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R Jr. Roskoski R Jr. Biochem Biophys Res Commun. 2005 Nov 11;337(1):1-13. doi: 10.1016/j.bbrc.2005.08.055. Biochem Biophys Res Commun. 2005. PMID: 16129412 Review.
Cited by
- Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy.
Sethi R, Kozin E, Remenschneider A, Meier J, VanderLaan P, Faquin W, Deschler D, Frankenthaler R. Sethi R, et al. Laryngoscope. 2014 Jan;124(1):188-195. doi: 10.1002/lary.24254. Epub 2013 Jul 9. Laryngoscope. 2014. PMID: 23775296 Free PMC article. Review. - Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment.
Parker BC, Zhang W. Parker BC, et al. Chin J Cancer. 2013 Nov;32(11):594-603. doi: 10.5732/cjc.013.10178. Chin J Cancer. 2013. PMID: 24206917 Free PMC article. - Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
Tognon CE, Rafn B, Cetinbas NM, Kamura T, Trigo G, Rotblat B, Okumura F, Matsumoto M, Chow C, Davare M, Pollak M, Mayor T, Sorensen PH. Tognon CE, et al. J Biol Chem. 2018 Aug 10;293(32):12502-12515. doi: 10.1074/jbc.RA117.000321. Epub 2018 Jun 14. J Biol Chem. 2018. PMID: 29903916 Free PMC article. - Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L, Ordulu Z, Dagogo-Jack I, Bossuyt V, Winters L, Taghian A, Smith BL, Ellisen LW, Kiedrowski LA, Lennerz JK, Bardia A, Spring LM. Mortensen L, et al. Oncologist. 2021 Oct;26(10):818-824. doi: 10.1002/onco.13880. Epub 2021 Jul 13. Oncologist. 2021. PMID: 34176200 Free PMC article. Review. - Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.
Krings G, Joseph NM, Bean GR, Solomon D, Onodera C, Talevich E, Yeh I, Grenert JP, Hosfield E, Crawford ED, Jordan RC, van Zante A, Zaloudek C, Shin SJ, Chen YY. Krings G, et al. Mod Pathol. 2017 Aug;30(8):1086-1099. doi: 10.1038/modpathol.2017.32. Epub 2017 May 26. Mod Pathol. 2017. PMID: 28548128
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous